Literature DB >> 10485460

Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients.

Y Daigo1, Y Furukawa, T Kawasoe, H Ishiguro, M Fujita, S Sugai, S Nakamori, G J Liefers, R A Tollenaar, C J van de Velde, Y Nakamura.   

Abstract

Activation of c-src, a cellular human gene homologous in sequence to the v-src gene of Rous sarcoma virus, had been thought to play an important role in the progression of several types of human cancers, without having undergone any genetic changes. However, recently truncating mutations at codon 531 of the c-src gene were reported in 12% of the advanced colon cancers, and it was also demonstrated that this change was activating, transforming, tumorigenic, and metastasis promoting. To investigate whether the codon 531-specific mutation could be involved in the carcinogenesis of colorectal cancer in the Japanese and Caucasian populations, we examined a total of 479 advanced colorectal cancers from 421 Japanese patients (46 of them with liver or lung metastases) and from 58 Caucasian patients (11 of them with liver metastases). Using the PCR-RFLP assay and additional single-strand conformation polymorphism analysis, we detected no genetic alteration in any of the advanced colorectal cancers. Our results suggest that the codon 531-specific mutational activation of c-src is unlikely to play a significant role in the malignant progression of colorectal cancers among most Japanese and Caucasian patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485460

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  c-src activating mutation analysis in Chinese patients with colorectal cancer.

Authors:  Ye-Xiong Tan; Han-Tao Wang; Peng Zhang; Zhong-Hua Yan; Guan-Long Dai; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

2.  Srcasm corrects Fyn-induced epidermal hyperplasia by kinase down-regulation.

Authors:  Weijie Li; Christine Marshall; Lijuan Mei; Joel Gelfand; John T Seykora
Journal:  J Biol Chem       Date:  2006-10-16       Impact factor: 5.157

3.  SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC.

Authors:  Sulin Zhang; Zhiwen Yang; Weilian Bao; Lixin Liu; Yan You; Xu Wang; Liming Shao; Wei Fu; Xinhui Kou; Weixing Shen; Congmin Yuan; Bin Hu; Wenzhen Dang; Kutty Selva Nandakumar; Hualiang Jiang; Mingyue Zheng; Xiaoyan Shen
Journal:  Autophagy       Date:  2019-07-04       Impact factor: 16.016

4.  Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer.

Authors:  Elizabeth M Poole; Karen Curtin; Li Hsu; Richard J Kulmacz; David J Duggan; Karen W Makar; Liren Xiao; Christopher S Carlson; Martha L Slattery; Bette J Caan; John D Potter; Cornelia M Ulrich
Journal:  Int J Mol Epidemiol Genet       Date:  2011-12-03

5.  Decreased Srcasm expression in esophageal squamous cell carcinoma in a Chinese population.

Authors:  Yu Qi; Xin Li; Liang Zhao; John T Seykora
Journal:  Anticancer Res       Date:  2010-09       Impact factor: 2.480

Review 6.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

7.  Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53.

Authors:  Liang Zhao; Weijie Li; Christine Marshall; Thomas Griffin; Matthew Hanson; Ryan Hick; Tzvete Dentchev; Erik Williams; Adrienne Werth; Christopher Miller; Hasan Bashir; Warren Pear; John T Seykora
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 8.  Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

Authors:  Ann Marie Egloff; Jennifer R Grandis
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

9.  Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.

Authors:  Audrey Sirvent; Christine Benistant; Serge Roche
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.